Yesterday the UK’s National Institute for Health and Clinical Excellence (NICE) concluded that £35,000 a year (about US$70,000) for new drugs that have been proven to have efficacy in the management of advanced renal cell carcinoma (kidney cancer) is more than the National Health Service (NHS) can afford.
Filed under: Business strategy, Drug approvals and regulation, Health and drug costs, health economics | Tagged: Add new tag, cancer, cost, economics, kidney, NICE | Comments Off
